KJHP
CRSP icon

K.J. Harrison & Partners’s CRISPR Therapeutics CRSP Stock Holding History

K.J. Harrison & Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,040
Closed -$268K – 145
2018
Q3 		$268K Sell
6,040
-50
-0.8% -$2.62K 0.07% 164
2018
Q2 		$358K Buy
+6,090
New +$347K 0.1% 153
2018
Q1 		– Sell
-23,525
Closed -$552K – 170
2017
Q4 		$552K Buy
+23,525
New +$447K 0.19% 123

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

K.J. Harrison & Partners's CRSP Position: Q4 2018 in Review

K.J. Harrison & Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2018, closing a stake of 6,040 shares — an estimated $268K sold.

K.J. Harrison & Partners first reported a position in CRSP in Q4 2017 and held it in 3 quarters. The position peaked at $552K in Q4 2017. 155 funds tracked by Wall St. Rank hold CRSP as of Q4 2018.

  • K.J. Harrison & Partners reported no remaining CRISPR Therapeutics position as of Q4 2018 after selling out during the quarter.
  • K.J. Harrison & Partners sold 6,040 CRISPR Therapeutics shares in Q4 2018, an estimated $268K.
  • K.J. Harrison & Partners first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 3 quarters.
  • K.J. Harrison & Partners's CRISPR Therapeutics position peaked at $552K in Q4 2017.
  • 155 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2018.

Based on K.J. Harrison & Partners's 13F filing for Q4 2018, filed 24 Jan 2019.